This article originally appeared in the Winter 2025 issue of EquiManagement. Sign up herefor a FREE subscription to EquiManagement’s quarterly digital or print magazine and any special issues.An SGLT2i might be a necessary premedication in advance of corticosteroid treatment in horses at high risk of laminitis. | Adobe Stock
In a February 2025 webinar, David Rendle, BVSc, MVM, CertEM(IntMed), DECEIM, FRCVS, RCVS, European Specialist in Equine Internal Medicine, shared updates to the information he presented on SGLT2 inhibitors (SGLT2i) at the 2024 AAEP Convention. SGLT2i work by blocking the kidneys’ proximal convoluted tubules to increase blood glucose secretion into urine, which helps reduce circulating insulin concentrations. SGLT2i act predominantly on the renal level, while SGLT1i act mainly on the intestines and pancreas.
GET FREE UNLIMITED ACCESS
Register today and get FREE unlimited access to all content from EquiManagement!
Get the best from EquiManagement delivered straight to your inbox once a week! Topics include horse care, disease alerts, and vet practitioner updates.
![[Aggregator] Downloaded image for imported item #18375](https://s3.amazonaws.com/wp-s3-equimanagement.com/wp-content/uploads/2025/09/30140031/EDCC-Unbranded-26-scaled-1-768x512.jpeg)
